Oral vs. IV HMAs: Considerations and Patient Guidance

Video content above is prompted by the following:

• What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient preferences?
• What are the key differences between oral azacitidine and oral decitabine-cedazuridine in terms of interchangeability and patient management, and how do you navigate these discussions with your patients, particularly if they were receiving intravenous azacitidine initially?